Mutation of the murine Bloom's syndrome gene produces global genome destabilization.

Mol Cell Biol

Department of Genetics, Harvard Medical School, 356 New Research Building, 77 Avenue Louis Pasteur, Boston, MA 02115, USA.

Published: September 2006

Bloom's syndrome (BS) is a genetic disorder characterized cellularly by increases in sister chromatid exchanges (SCEs) and numbers of micronuclei. BS is caused by mutation in the BLM DNA helicase gene and involves a greatly enhanced risk of developing the range of malignancies seen in the general population. With a mouse model for the disease, we set out to determine the relationship between genomic instability and neoplasia. We used a novel two-step analysis to investigate a panel of eight cell lines developed from mammary tumors that appeared in Blm conditional knockout mice. First, the panel of cell lines was examined for instability. High numbers of SCEs were uniformly seen in members of the panel, and several lines produced chromosomal instability (CIN) manifested by high numbers of chromosomal structural aberrations (CAs) and chromosome missegregation events. Second, to see if Blm mutation was responsible for the CIN, time-dependent analysis was conducted on a tumor line harboring a functional floxed Blm allele. The floxed allele was deleted in vitro, and mutant as well as control subclones were cultured for 100 passages. By passage 100, six of nine mutant subclones had acquired high CIN. Nine mutant subclones produced 50-fold more CAs than did nine control subclones. Finally, chromosome loss preceded the appearance of CIN, suggesting that this loss provides a potential mechanism for the induction of instability in mutant subclones. Such aneuploidy or CIN is a universal feature of neoplasia but has an uncertain function in oncogenesis. Our results show that Blm gene mutation produces this instability, strengthening a role for CIN in the development of human cancer.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1592839PMC
http://dx.doi.org/10.1128/MCB.00296-06DOI Listing

Publication Analysis

Top Keywords

mutant subclones
12
bloom's syndrome
8
panel cell
8
cell lines
8
high numbers
8
control subclones
8
cin
6
blm
5
instability
5
subclones
5

Similar Publications

To investigate the clinicopathological and molecular genetic features of POLE mutant endometrioid carcinoma. Genetic test data of 230 cases of endometrial carcinoma that underwent surgical resection and molecular typing by next generation sequencing in the First Medical Center of Chinese PLA General Hospital from January 2021 to June 2023 were retrospectively analyzed. Seventeen cases of endometrioid carcinoma with POLE mutation were selected.

View Article and Find Full Text PDF

Cancer evolution is a multifaceted process leading to dysregulation of cellular expansion and differentiation through somatic mutations and epigenetic dysfunction. Clonal expansion and evolution is driven by cell-intrinsic and -extrinsic selective pressures, which can be captured with increasing resolution by single-cell and bulk DNA sequencing. Despite the extensive genomic alterations revealed in profiling studies, there remain limited experimental systems to model and perturb evolutionary processes.

View Article and Find Full Text PDF

Loss-of-function mutations in the tumour suppressor APC are an initial step in intestinal tumorigenesis. APC-mutant intestinal stem cells outcompete their wild-type neighbours through the secretion of Wnt antagonists, which accelerates the fixation and subsequent rapid clonal expansion of mutants. Reports of polyclonal intestinal tumours in human patients and mouse models appear at odds with this process.

View Article and Find Full Text PDF
Article Synopsis
  • Temozolomide treatment for IDH-mutant gliomas can lead to complications like hypermutation and malignant transformation, but the progression of untreated low-grade gliomas is not well-explored.
  • A study analyzed tumors from 19 patients with IDH-mutant Grade 2 astrocytomas that were not treated with temozolomide or radiotherapy prior to recurrence, revealing that most recurrences were of a higher grade and frequently featured new copy number variations (CNVs) not found in the original tumors.
  • The research found that out of 19 cases, 89.5% exhibited significant genetic alterations at recurrence, but no hypermutation occurred, suggesting that untreated IDH-mutant astrocytomas
View Article and Find Full Text PDF
Article Synopsis
  • Mutations in the IDH gene are crucial for the development of astrocytoma and oligodendroglioma, but their role in tumor maintenance and aggressive transformation is still unclear.
  • Researchers observed an unusual case of IDH-mutant astrocytoma that transformed into two distinct types: one with IDH mutations and another without, showing differing characteristics in aggression.
  • The IDH-wild-type component lacked the IDH mutation due to chromosome loss, and also acquired additional genetic changes, indicating that these tumors may become independent of IDH mutations and develop resistance to treatments targeting those mutations.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!